Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 277Neoplasms 202Prostatic Neoplasms 118Polycystic Ovary Syndrome 114Colorectal Neoplasms 104Carcinoma, Hepatocellular 103Carcinoma, Non-Small-Cell Lung 88Lung Neoplasms 70Stomach Neoplasms 62Precursor Cell Lymphoblastic Leukemia-Lymphoma 60Pain 59Neoplasm Metastasis 54Multiple Myeloma 52Pancreatic Neoplasms 46Keratosis, Actinic 46Pain, Postoperative 43Head and Neck Neoplasms 43Leukemia, Myeloid, Acute 40Leiomyoma 39Recurrence 38Liver Neoplasms 38Colonic Neoplasms 37Uterine Cervical Neoplasms 35Lymphoma 35Brain Neoplasms 34Infertility 33Papillomavirus Infections 32Ovarian Neoplasms 31Lymphoma, Follicular 31Lymphoma, Non-Hodgkin 30

Interventions

Vortioxetine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Unipolar Major Depression × Clear all
NCT02637466 2016-09-30

Vortioxetine for MDD, Cognition, and Systemic Inflammatory Biomarkers

University of Miami

Phase 4 Withdrawn
Breast

Unipolar Major Depression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡